Top Level Navigation

Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia

Pharming NV and Esteve are developing Rhucin, a recombinant human C1 esterase inhibitor. Rhucin is currently undergoing phase III clinical trials in North America and is awaiting regulatory approval in Western Europe for the treatment of prophylactic and acute hereditary angioedema. Pharming is also investigating Rhucin for the potential treatment of cerebral ischemic injury. [References: 110].

Mar;9(3):310-323

Not available online.

Comments are closed.